EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

Examples include exenatide and lixisenatide. Ozempic: Novo Nordisk’s name-brand version of injectable semaglutide to help ...

Novo Holdings will then sell three Catalent manufacturing sites to Novo Nordisk (NVO), which should help increase production ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

No adequate supply? Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo Nordisk. (Photo: James ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot, MariTide, causes excessive bone mineral density loss.Please watch the video at Investors.com - How Novo ...